A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Immunogenicity of the ExPEC4V (JNJ-63871860) Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Subjects Aged 18 Years and Older
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs JNJ 63871860 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Research & Development
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2018 New trial record